FDA approves Roche ’s MabThera/Rituxan (rituximab) for pemphigus vulgaris

Roche announced today that the US Food and Drug Administration (FDA) has approved MabThera/Rituxan ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news